Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Yogurt Probiotics Used to Fight Cancer

By BiotechDaily International staff writers
Posted on 04 Apr 2013
Probiotics, similar to those found in yogurt, which are found to enhance digestive health, are now being considered as a possible weapon to be used in the war against cancer.

This is the focus of investigators from the Cancer Institute of New Jersey (New Brunswick, USA), a Center of Excellence of the University of Medicine and Dentistry of New Jersey (UMDNJ)-Robert Wood Johnson Medical School, who are studying the effectiveness of probiotics as they relate to the outcomes of bone marrow transplant for blood cancer patients.

Some patients with lymphoma, leukemia, and myeloma are treated with an allogeneic bone marrow transplant where the donor is a blood relative or is unrelated but has the same tissue type. Donated cells can generate an immune attack against cancer cells in the patient, but they can also attack normal healthy cells and tissues. This attack, known as graft-versus-host disease (GVHD), is one of the key problems of transplantation and occurs in the gastrointestinal (GI) tract in 25%–40% of patients who undergo the allogeneic procedure.

When the GI tract breaks down, bacteria in the colon can invade the body and cause nasty infections that trigger the immune system. GVHD can then advance to the liver and other organs. Probiotics are known to decrease the growth of specific types of bacteria. Investigators from the Cancer Institute of New Jersey, who have already determined the probiotic Lactobacillus GG is safe in relation to GVHD, are now exploring its effectiveness as part of the PERFECT (Probiotic Enteric Regimen For Easing Complications of Transplant) trial. The research is being led by Roger Strair, MD, PhD, chief of hematologic alignancies/hematopoietic stem cell transplantation at the Cancer Institute of New Jersey.

“By further exploring the effects of probiotics on graft-versus-host-disease, we may be able to identify methods of preventing infection. We are grateful for their support,” noted Dr. Strair, professor of medicine at UMDNJ-Robert Wood Johnson Medical School.

Related Links:
Cancer Institute of New Jersey



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Alternative splicing produces two protein isoforms (Photo courtesy of Wikimedia Commons).

Key Regulator of Cancer-Inducing Alternative Splicing Identified

Cancer researchers have identified the splicing factor RBM4 (RNA-binding protein 4) as a key determinant in processes that prevent tumor development and spread. RBM4 is known to be crucial to gene splicing... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel
Image: Leica Microsystems launches the inverted research microscope platform Leica DMi8 (Photo courtesy of Leica Microsystems).

New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.